Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel

Fourniols, Thibaut; Bastien, Estelle; Canevat, Alizée; Féron, Olivier; Préat, Véronique

doi:10.1016/j.ijpharm.2020.119337

Cited by 19 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LNC are physically stable bio-inspired lipoprotein-like nanovectors characterized by a small uniform size (less than 100 nm) and an oily core surrounded by a pegylated surfactant tensioactive shell (Huynh et al., 2009 ). LNC were reported to improve the therapeutic profile of anti-cancer drugs (Resnier et al, 2017 ; Fourniols et al, 2020 ), enhance tumor localization and intracellular drug delivery (Huynh et al., 2011 ; Karim et al., 2018 ) and inhibit the P-glycoprotein efflux pump (Garcion et al., 2006 ). MFS, an amphiphilic membrane active alkylphospholipid (APL) synthetically derived from cell membrane components, shows multiple biological actions including anticancer activity (Kaleağasıoğlu et al., 2019 , 2020).…”

Section: Introductionmentioning

confidence: 99%

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules

et al. 2021

View full text Add to dashboard Cite

Itraconazole (ITC), a well-tolerated antifungal drug, exerts multiple anticancer effects which justified its preclinical and clinical investigation as potential anti-cancer agent with reduced side effects. Enhancement of ITC anti-cancer efficacy would bring valuable benefits to patients. We propose herein lipid nanocapsules (LNCs) modified with a subtherapeutic dose of miltefosine (MFS) as a membrane bioactive amphiphilic additive (M-ITC-LNC) for the development of an ITC nanoformulation with enhanced anticancer activity compared with ITC solution (ITC-sol) and unmodified ITC-LNC. Both LNC formulations showed a relatively small size (43–46 nm) and high entrapment efficiency (>97%), though ITC release was more sustained by M-ITC-LNC. Cytotoxicity studies revealed significantly greater anticancer activity and selectivity of M-ITC-LNC for MCF-7 breast cancer cells compared with ITC-sol and ITC-LNC. This trend was substantiated by in vivo findings following a 14 day-treatment of murine mammary pad Ehrlich tumors. M-ITC-LNC showed the greatest enhancement of the ITC-induced tumor growth inhibition, proliferation, and necrosis. At the molecular level, the tumor content of Gli 1, caspase-3, and vascular endothelial growth factor verified superiority of M-ITC-LNC in enhancing the ITC antiangiogenic, apoptotic, and Hedgehog pathway inhibitory effects. Finally, histopathological and biochemical analysis indicated greater reduction of ITC systemic toxicity by M-ITC-LNC. Superior performance of M-ITC-LNC was attributed to the effect of MFS on the structural and release properties of LNC coupled with its distinct bioactivities. In conclusion, MFS-modified LNC provides a simple nanoplatform integrating the potentials of LNC and MFS for enhancing the chemotherapeutic efficacy of ITC and possibly other oncology drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The depletion of CAFs contributes to reducing interstitial pressure, thereby improving drug delivery. Fourniols et al [233] used liposomes as carriers to test the effects of various cytotoxic drugs on CAFs, and the results showed that acridine yellow and paclitaxel could effectively kill CAFs and inhibit the growth of 3D tumor spheres in fibroblast and cancer cell coculture systems. Nicolás et al [234] took advantage of the off-target effects of nanomedicines in tumor tissues to deliver Fe 3 O 4 -Au hybrid nanoparticles to CAFs that are associated with liver cancer, irradiated them with a laser, and used photothermal effects to eliminate the CAFs and inhibit tumor progression.…”

Section: Nanomedicine Improves Immunotherapy By Regulating the Tmementioning

confidence: 99%

Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy

Huang,

Fan,

2024

Asian Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…It was also shown that paclitaxel (PTX) was more effective against cancer-associated fibroblasts (CAFs) when encapsulated in LNCs. 84 The recent studies by Morteza Eskandani’s research group also suggested the need to incorporate ACF into solid lipid nanoparticles (SLNs). 85 ACF-SLN cytotoxicity studies against A549 human epithelial carcinoma cells showed that ACF-SLN was more effective than free ACF.…”

Section: Anticancer Properties Of Acriflavinementioning

confidence: 99%

“…This led to a reduction in the number of drug administrations from 12 to 2. It was also shown that paclitaxel (PTX) was more effective against cancer-associated fibroblasts (CAFs) when encapsulated in LNCs . The recent studies by Morteza Eskandani’s research group also suggested the need to incorporate ACF into solid lipid nanoparticles (SLNs) .…”

Section: Anticancer Properties Of Acriflavinementioning

confidence: 99%

Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art

2022

View full text Add to dashboard Cite

Acriflavine (ACF) has been known for years as an antibacterial drug. The identification of key oncogenic mechanisms has brought, in recent years, a significant increase in studies on ACF as a multipurpose drug that would improve the prognosis for cancer patients. ACF interferes with the expression of the hypoxia inducible factor, thus acting on metastatic niches of tumors and significantly enhancing the effects of other anticancer therapies. It has been recognized as the most potent HIF-1 inhibitor out of the 336 drugs approved by the FDA. This work presents up-to-date knowledge about the mechanisms of action of ACF and its related prodrug systems in the context of anticancer and SARS-CoV-2 inhibitory properties. It explains the multitask nature of this drug and suggests mechanisms of ACF’s action on the coronavirus. Other recent reports on ACF-based systems as potential antibacterial and antiviral drugs are also described.

show abstract

Inhibition of colorectal cancer-associated fibroblasts by lipid nanocapsules loaded with acriflavine or paclitaxel

Cited by 19 publications

References 39 publications

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules

Enhancing the in vitro and in vivo activity of itraconazole against breast cancer using miltefosine-modified lipid nanocapsules

Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy

Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art

Contact Info

Product

Resources

About